462 related articles for article (PubMed ID: 25927483)
1. Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study.
Azouz W; Chetcuti P; Hosker H; Saralaya D; Chrystyn H
BMC Pulm Med; 2015 May; 15():47. PubMed ID: 25927483
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blinded, double-dummy efficacy and safety study of budesonide-formoterol Spiromax® compared to budesonide-formoterol Turbuhaler® in adults and adolescents with persistent asthma.
Virchow JC; Rodriguez-Roisin R; Papi A; Shah TP; Gopalan G
BMC Pulm Med; 2016 Mar; 16():42. PubMed ID: 26987997
[TBL] [Abstract][Full Text] [Related]
3. Budesonide + formoterol delivered via Spiromax
Lewis A; Torvinen S; Dekhuijzen PNR; Chrystyn H; Melani A; Zöllner Y; Kolbe K; Watson AT; Blackney M; Plich A
Respir Med; 2017 Aug; 129():179-188. PubMed ID: 28732829
[TBL] [Abstract][Full Text] [Related]
4. Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions.
Canonica GW; Arp J; Keegstra JR; Chrystyn H
J Aerosol Med Pulm Drug Deliv; 2015 Oct; 28(5):309-19. PubMed ID: 26352860
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study.
Price DB; Thomas V; Richard Dekhuijzen PN; Bosnic-Anticevich S; Roche N; Lavorini F; Raju P; Freeman D; Nicholls C; Small IR; Sims E; Safioti G; Canvin J; Chrystyn H
BMC Pulm Med; 2018 Jun; 18(1):107. PubMed ID: 29954359
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK.
Voorham J; Roche N; Benhaddi H; van der Tol M; Carter V; van Boven JFM; Bjermer L; Miravitlles M; Price DB
BMJ Open; 2018 Oct; 8(10):e022051. PubMed ID: 30368448
[TBL] [Abstract][Full Text] [Related]
7. Onset of action of budesonide/formoterol Spiromax(®) compared with budesonide/formoterol Turbuhaler(®) in patients with COPD.
Cazzola M; Ora J; Di Paolo A; Puxeddu E; Calzetta L; Rogliani P
Pulm Pharmacol Ther; 2016 Aug; 39():48-53. PubMed ID: 27344046
[TBL] [Abstract][Full Text] [Related]
8. Real-life budesonide and formoterol dose emission from the medium and high strength fixed dosed combinations in a Spiromax® dry powder inhaler using inhalation profiles from patients with chronic obstructive pulmonary disease.
Bagherisadeghi G; Chrystyn H; Abadelah M; Larhrib EH
Eur J Pharm Sci; 2019 Nov; 139():105059. PubMed ID: 31472254
[TBL] [Abstract][Full Text] [Related]
9. Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study.
Janson C; Lööf T; Telg G; Stratelis G; Nilsson F
NPJ Prim Care Respir Med; 2016 Nov; 26():16053. PubMed ID: 27853177
[TBL] [Abstract][Full Text] [Related]
10. The inhalation characteristics of patients when they use different dry powder inhalers.
Azouz W; Chetcuti P; Hosker HS; Saralaya D; Stephenson J; Chrystyn H
J Aerosol Med Pulm Drug Deliv; 2015 Feb; 28(1):35-42. PubMed ID: 24815999
[TBL] [Abstract][Full Text] [Related]
11. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices.
van der Palen J; Thomas M; Chrystyn H; Sharma RK; van der Valk PD; Goosens M; Wilkinson T; Stonham C; Chauhan AJ; Imber V; Zhu CQ; Svedsater H; Barnes NC
NPJ Prim Care Respir Med; 2016 Nov; 26():16079. PubMed ID: 27883002
[TBL] [Abstract][Full Text] [Related]
12. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler.
Chrystyn H; Safioti G; Keegstra JR; Gopalan G
Int J Pharm; 2015 Aug; 491(1-2):268-76. PubMed ID: 26043823
[TBL] [Abstract][Full Text] [Related]
13. A Comparison of Short-Term Growth During Treatment with Two Dry Powder Combinations of Inhaled Corticosteroids and Long-Acting β₂-Agonists.
Wolthers OD; Shah T
J Aerosol Med Pulm Drug Deliv; 2015 Jun; 28(3):182-8. PubMed ID: 25166221
[TBL] [Abstract][Full Text] [Related]
14. Patient Satisfaction and Clinical Outcomes with Budesonide plus Formoterol Spiromax for Asthma and Chronic Obstructive Pulmonary Disease: A Real-World, Observational Trial.
Gillissen A; Gessner C; Hechenbichler K; Herth FJF; Juenemann R; Kanniess F; Kardos P; Lommatzsch M; Schneidereit R; Windisch W
Respiration; 2019; 97(4):292-301. PubMed ID: 30391944
[TBL] [Abstract][Full Text] [Related]
15. Bioequivalence of budesonide plus formoterol (BF) Spiromax® and BF Turbohaler® (with and without charcoal block) in healthy volunteers.
Weisfeld L; Shu Y; Shah TP
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):593-602. PubMed ID: 26042485
[TBL] [Abstract][Full Text] [Related]
16. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
[TBL] [Abstract][Full Text] [Related]
17. Real-life association between inhaler technique, patient preference and asthma control in patients with uncontrolled asthma switched to budesonide/formoterol DuoResp® Spiromax® combination.
Roche N; Aguilaniu B; Paternotte S; Dallery N
J Asthma; 2022 Apr; 59(4):765-774. PubMed ID: 33493074
[No Abstract] [Full Text] [Related]
18. DuoResp
van der Palen J; Cerveri I; Roche N; Singh D; Plaza V; Gonzalez C; Patino O; Scheepstra I; Safioti G; Backer V
J Asthma; 2020 Oct; 57(10):1110-1118. PubMed ID: 31293211
[No Abstract] [Full Text] [Related]
19. Inhaler technique mastery and maintenance in healthcare professionals trained on different devices.
Bosnic-Anticevich S; Callan C; Chrystyn H; Lavorini F; Nikolaou V; Kritikos V; Dekhuijzen PNR; Roche N; Bjermer L; Rand C; Zwar N; Price DB
J Asthma; 2018 Jan; 55(1):79-88. PubMed ID: 28332886
[TBL] [Abstract][Full Text] [Related]
20. Real life dose emission characterization using COPD patient inhalation profiles when they inhaled using a fixed dose combination (FDC) of the medium strength Symbicort
Bagherisadeghi G; Larhrib EH; Chrystyn H
Int J Pharm; 2017 Apr; 522(1-2):137-146. PubMed ID: 28254655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
